Median Technologies’ eyonis® LCS Obtains CE Marking

Business Wire·Jul 3

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Median Technologies' eyonis LCS, a software for lung cancer screening, has obtained CE marking. This certification indicates that the product meets certain safety and performance standards in the european market. The company also recently received FDA 510(k) clearance for the software in the US market.

Full coverage

Median Technologies to Showcase eyonis® LCS, Its AI/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology

Business Wire·Mar 2

Median Technologies Receives FDA 510(k) Clearance for eyonis® LCS, the First AI Tech-Based Detection and Diagnosis Device for Lung Cancer Screening

BioSpace·Feb 9

Median Technologies Secures CE Mark for its Eyonis LCS Software

Idéal Investisseur·Jul 3

DermaSensor Announces Class IIb CE Mark and Collaboration with NHS, Marking the Beginning of Its Global Expansion

Yahoo Finance·Jun 10

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

Yahoo Finance·Mar 31

View original report at Business Wire ↗

Fetching the latest headlines…